Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pugliese, G.
Right arrow Articles by Di Mario, U.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pugliese, G.
Right arrow Articles by Di Mario, U.
Social Bookmarking
 Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes, Vol 46, Issue 11 1881-1887, Copyright © 1997 by American Diabetes Association


ARTICLES

Upregulation of mesangial growth factor and extracellular matrix synthesis by advanced glycation end products via a receptor-mediated mechanism

G Pugliese, F Pricci, G Romeo, F Pugliese, P Mene, S Giannini, B Cresci, G Galli, CM Rotella, H Vlassara and U Di Mario
Department of Experimental Medicine, 2nd Institute of Internal Medicine, La Sapienza University, Rome, Italy.

Enhanced advanced glycosylation end product (AGE) formation has been shown to participate in the pathogenesis of diabetes-induced glomerular injury by mediating the increased extracellular matrix (ECM) deposition and altered cell growth and turnover leading to mesangial expansion. These effects could be exerted via an AGE-receptor-mediated upregulation of growth factors, such as the IGFs and transforming growth factor-beta (TGF-beta). We tested this hypothesis in human and rat mesangial cells grown on nonglycated or native bovine serum albumin (BSA), glycated BSA with AGE formation (BSA-AGE), or glycated BSA in which AGE formation was prevented by the use of aminoguanidine (BSA-AM), in the presence or absence of an antibody, alpha-p60, directed against the p60/OST protein named AGE-receptor 1 (AGE-R1), or normal control (pre-immune) serum. The mRNA and/or protein levels of IGF-I, IGF-II, IGF receptors, IGF binding proteins (IGFBPs), TGF-beta1 and the ECM components fibronectin, laminin, and collagen IV were measured, together with cell proliferation. Both human and rat mesangial cells grown on BSA-AGE showed increased IGF-I and total and bioactive TGF-beta medium levels and enhanced IGF-I, IGF-II, and TGF-beta1 gene expression, compared with cells grown on BSA, whereas total IGFBP and IGFBP-3 medium content, IGF receptor density and affinity, and IGF-I receptor transcripts were unchanged. Moreover, cells grown on BSA-AGE showed increased ECM protein and mRNA levels versus cells cultured on BSA, whereas cell proliferation was unchanged in human mesangial cells and slightly reduced in rat mesangial cells. Growing cells on BSA-AM did not affect any of the measured parameters. Co-incubation of BSA-AGE with anti-AGE-R1, but not with pre-immune serum, prevented AGE-induced increases in IGF-I, TGF-beta1, and ECM production or gene expression; anti-AGE-R1 also reduced growth factor and matrix synthesis in cells grown on BSA. These results demonstrate that mesangial IGF and TGF-beta1 synthesis is upregulated by AGE-modified proteins through an AGE-receptor-mediated mechanism. The parallelism with increased ECM production raises the speculation that the enhanced synthesis of these growth factors resulting from advanced nonenzymatic glycation participates in the pathogenesis of hyperglycemia-induced mesangial expansion.
Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Am. Soc. Nephrol.Home page
K. Yozai, K. Shikata, M. Sasaki, A. Tone, S. Ohga, H. Usui, S. Okada, J. Wada, R. Nagase, D. Ogawa, et al.
Methotrexate Prevents Renal Injury in Experimental Diabetic Rats via Anti-Inflammatory Actions
J. Am. Soc. Nephrol., November 1, 2005; 16(11): 3326 - 3338.
[Abstract] [Full Text] [PDF]


Home page
Br. J. Ophthalmol.Home page
S McFarlane, J V Glenn, A M Lichanska, D A C Simpson, and A W Stitt
Characterisation of the advanced glycation endproduct receptor complex in the retinal pigment epithelium
Br. J. Ophthalmol., January 1, 2005; 89(1): 107 - 112.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
B. F. Schrijvers, A. S. De Vriese, and A. Flyvbjerg
From Hyperglycemia to Diabetic Kidney Disease: The Role of Metabolic, Hemodynamic, Intracellular Factors and Growth Factors/Cytokines
Endocr. Rev., December 1, 2004; 25(6): 971 - 1010.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
V. Thallas-Bonke, C. Lindschau, B. Rizkalla, L. A. Bach, G. Boner, M. Meier, H. Haller, M. E. Cooper, and J. M. Forbes
Attenuation of Extracellular Matrix Accumulation in Diabetic Nephropathy by the Advanced Glycation End Product Cross-Link Breaker ALT-711 via a Protein Kinase C-{alpha}-Dependent Pathway
Diabetes, November 1, 2004; 53(11): 2921 - 2930.
[Abstract] [Full Text] [PDF]


Home page
IOVSHome page
H. Ida, K. Ishibashi, K. Reiser, L. M. Hjelmeland, and J. T. Handa
Ultrastructural Aging of the RPE-Bruch's Membrane-Choriocapillaris Complex in the D-Galactose-Treated Mouse
Invest. Ophthalmol. Vis. Sci., July 1, 2004; 45(7): 2348 - 2354.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
J. H. Li, W. Wang, X. R. Huang, M. Oldfield, A. M. Schmidt, M. E. Cooper, and H. Y. Lan
Advanced Glycation End Products Induce Tubular Epithelial-Myofibroblast Transition through the RAGE-ERK1/2 MAP Kinase Signaling Pathway
Am. J. Pathol., April 1, 2004; 164(4): 1389 - 1397.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
A. Flyvbjerg, L. Denner, B. F. Schrijvers, R. G. Tilton, T. H. Mogensen, S. R. Paludan, and R. Rasch
Long-Term Renal Effects of a Neutralizing RAGE Antibody in Obese Type 2 Diabetic Mice
Diabetes, January 1, 2004; 53(1): 166 - 172.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
S. Okada, K. Shikata, M. Matsuda, D. Ogawa, H. Usui, Y. Kido, R. Nagase, J. Wada, Y. Shikata, and H. Makino
Intercellular Adhesion Molecule-1-Deficient Mice Are Resistant Against Renal Injury After Induction of Diabetes
Diabetes, October 1, 2003; 52(10): 2586 - 2593.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
L. Lasagni, M. Francalanci, F. Annunziato, E. Lazzeri, S. Giannini, L. Cosmi, C. Sagrinati, B. Mazzinghi, C. Orlando, E. Maggi, et al.
An Alternatively Spliced Variant of CXCR3 Mediates the Inhibition of Endothelial Cell Growth Induced by IP-10, Mig, and I-TAC, and Acts as Functional Receptor for Platelet Factor 4
J. Exp. Med., June 2, 2003; 197(11): 1537 - 1549.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
R. M. Mason and N. A. Wahab
Extracellular Matrix Metabolism in Diabetic Nephropathy
J. Am. Soc. Nephrol., May 1, 2003; 14(5): 1358 - 1373.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
T. Wendt, N. Tanji, J. Guo, B. I. Hudson, A. Bierhaus, R. Ramasamy, B. Arnold, P. P. Nawroth, S. F. Yan, V. D'Agati, et al.
Glucose, Glycation, and RAGE: Implications for Amplification of Cellular Dysfunction in Diabetic Nephropathy
J. Am. Soc. Nephrol., May 1, 2003; 14(5): 1383 - 1395.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
R. Candido, J. M. Forbes, M. C. Thomas, V. Thallas, R. G. Dean, W. C. Burns, C. Tikellis, R. H. Ritchie, S. M. Twigg, M. E. Cooper, et al.
A Breaker of Advanced Glycation End Products Attenuates Diabetes-Induced Myocardial Structural Changes
Circ. Res., April 18, 2003; 92(7): 785 - 792.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S.-i. Yamagishi, Y. Inagaki, T. Okamoto, S. Amano, K. Koga, M. Takeuchi, and Z. Makita
Advanced Glycation End Product-induced Apoptosis and Overexpression of Vascular Endothelial Growth Factor and Monocyte Chemoattractant Protein-1 in Human-cultured Mesangial Cells
J. Biol. Chem., May 31, 2002; 277(23): 20309 - 20315.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
S. M. Twigg, A. H. Joly, M. M. Chen, J. Tsubaki, H.-S. Kim, V. Hwa, Y. Oh, and R. G. Rosenfeld
Connective Tissue Growth Factor/IGF-Binding Protein-Related Protein-2 Is a Mediator in the Induction of Fibronectin by Advanced Glycosylation End-Products in Human Dermal Fibroblasts
Endocrinology, April 1, 2002; 143(4): 1260 - 1269.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
G. PUGLIESE, F. PRICCI, C. IACOBINI, G. LETO, L. AMADIO, P. BARSOTTI, L. FRIGERI, D. K. HSU, H. VLASSARA, F.-T. LIU, et al.
Accelerated diabetic glomerulopathy in galectin-3/AGE receptor 3 knockout mice
FASEB J, November 1, 2001; 15(13): 2471 - 2479.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
S. M. Twigg, M. M. Chen, A. H. Joly, S. D. Chakrapani, J. Tsubaki, H.-S. Kim, Y. Oh, and R. G. Rosenfeld
Advanced Glycosylation End Products Up-Regulate Connective Tissue Growth Factor (Insulin-Like Growth Factor-Binding Protein-Related Protein 2) in Human Fibroblasts: A Potential Mechanism for Expansion of Extracellular Matrix in Diabetes Mellitus
Endocrinology, May 1, 2001; 142(5): 1760 - 1769.
[Abstract] [Full Text]


Home page
Nephrol Dial TransplantHome page
J. Iglesias and J. S. Levine
Albuminuria and renal injury--beware of proteins bearing gifts
Nephrol. Dial. Transplant., February 1, 2001; 16(2): 215 - 218.
[Full Text] [PDF]


Home page
Int J EpidemiolHome page
L. Dow and S. Ebrahim
Commentary: Lung function and risk of fatal and non-fatal stroke--The Copenhagen City Heart Study
Int. J. Epidemiol., February 1, 2001; 30(1): 152 - 153.
[Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
V. Scivittaro, M. B. Ganz, and M. F. Weiss
AGEs induce oxidative stress and activate protein kinase C-beta II in neonatal mesangial cells
Am J Physiol Renal Physiol, April 1, 2000; 278(4): F676 - F683.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
L. A. Bach, R. Dean, S. Youssef, and M. E. Cooper
Aminoguanidine ameliorates changes in the IGF system in experimental diabetic nephropathy
Nephrol. Dial. Transplant., March 1, 2000; 15(3): 347 - 354.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 1997 by the American Diabetes Association.